FDA Urges More Switch Sponsor Efforts At Pre-Clinical Stage
This article was originally published in The Tan Sheet
Executive Summary
Firms submitting switch applications should put more focus on pre-clinical testing, according to Dr. Andrea Leonard-Segal, director of the Division of Nonprescription Clinical Evaluation in FDA's Center for Drug Evaluation and Research